New Test to Predict Primary Melanoma Progression

New Test to Predict Primary Melanoma Progression

21 January 2020

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.

The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.

The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.

‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.

‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.

Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.

While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.

Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.

‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’ 

Australasian Melanoma Conference AMC2021
19 Nov - 20 Nov 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.

Honouring Ben's life by supporting the next generation of melanoma researchers
30 Aug 2021

Honouring Ben's life by supporting the next generation of melanoma researchers

Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.

MIA's annual Research Retreat 2021
20 Aug 2021

MIA's annual Research Retreat 2021

More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.

Understanding the needs of Stage III melanoma patients when choosing treatments.
28 Jul 2021

Understanding the needs of Stage III melanoma patients when choosing treatments.

Independent researchers at The University of Sydney are seeking patient feedback.

Community Fundraising Wrap Up Apr-June 2021
21 Jul 2021

Community Fundraising Wrap Up Apr-June 2021

A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.

Tags: melanoma
Patients paying it forward
19 Jul 2021

Patients paying it forward

Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients. 

Tags: melanoma
Research boost to improve outcomes for melanoma patients
15 Jul 2021

Research boost to improve outcomes for melanoma patients

MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.

Tags: melanoma
Amie St Clair 10th Annual Ball
25 Jun 2022

Amie St Clair 10th Annual Ball

Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!   

Riverina Melanoma Ride
31 Mar - 07 Apr 2022

Riverina Melanoma Ride

Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!

Melanoma Clinical Trial opens in Wagga
23 Jun 2021

Melanoma Clinical Trial to open in Wagga

Riverina patients gain access to potentially life saving immunotherapy treatment close to home.

Tags: melanoma
Queen's Birthday Honour for Professor Richard Scolyer
13 Jun 2021

 Queen's Birthday Honour for Professor Richard Scolyer

MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia. 

Tags: melanoma
Sharing our research on the global stage at 2021 ASCO Annual Meeting
07 Jun 2021

Sharing our research on the global stage at 2021 ASCO Annual Meeting

Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21. 

Tags: melanoma
Australian researchers lead world in successful trial of new cancer treatment
03 Jun 2021

Australian researchers lead world in successful trial of new cancer treatment.

In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.

Tags: melanoma
Thank you doesn't seem enough for our melanoma nurses.
28 May 2021

Thank you doesn't seem enough for our melanoma nurses.

Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.

Tags: melanoma
Sharing our knowledge of melanoma on the global stage
20 Apr 2021

Sharing our knowledge of melanoma on the global stage

As leaders in the field of melanoma, clinicians and researchers from MIA shared their knowledge at the virtual 10th World Congress of Melanoma. 

Tags: melanoma
Community Fundraising Wrap Up Jan-Mar 2021
15 Apr 2021

Community Fundraising Wrap Up Jan-Mar 2021

The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.

Tags: melanoma
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 Apr 2021

Melanoma patients and their families urged to speak up and put national spotlight on melanoma.

Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.

Tags: melanoma